Archives
-
Atorvastatin and Ferroptosis in Hepatocellular Carcinoma
2026-08-31
This 2025 study combines a ferroptosis-related prognostic signature with Connectivity Map drug screening to identify Atorvastatin as a candidate intervention for hepatocellular carcinoma. Computational results and in vitro and in vivo experiments support an association between Atorvastatin exposure, ferroptosis-related responses, and reduced HCC growth and migration, while further validation is needed before clinical translation.
-
Ferroptosis Signature Identifies Atorvastatin in HCC
2026-08-31
Wang and colleagues developed a four-gene ferroptosis-related prognostic signature for hepatocellular carcinoma and used Connectivity Map analysis to identify Atorvastatin as a candidate treatment. In vitro and in vivo experiments linked Atorvastatin exposure with ferroptosis-like tumor suppression, reduced HCC cell migration, and impaired tumor growth, while also highlighting the need for further mechanistic and clinical validation.
-
Ferroptosis Signature and Atorvastatin in HCC
2026-08-30
The reference study combines a four-gene ferroptosis-related prognostic signature with Connectivity Map screening to identify Atorvastatin as a candidate agent for hepatocellular carcinoma. Computational prioritization followed by in vitro and in vivo validation linked Atorvastatin treatment with ferroptosis, reduced tumor-cell growth, and impaired migration, while leaving clinical efficacy and the precise molecular mechanism for future study.
-
15-PGDH Inhibition Supports Muscle Repair During Weight Loss
2026-08-29
A 2026 PNAS study identifies 15-PGDH inhibition as a strategy for improving skeletal muscle regeneration during semaglutide-associated weight loss. In obese mice, combined treatment preserved weight-loss efficacy while improving regenerative myofiber growth, muscle quality, and recovery of force after injury.
-
CCG-1423 RhoA Inhibitor: Workflow Guide
2026-08-28
CCG-1423 is a pathway-focused RhoA inhibitor for separating MRTF-A nuclear signaling from broader cytoskeletal responses. This guide translates its mechanism into practical cancer research, apoptosis, invasion, barrier, and exploratory viral-entry workflows while emphasizing controls and interpretation limits.
-
Protein A/G Magnetic Co-IP/IP Kit for BATF2 Studies
2026-08-28
A practical workflow for testing BATF2–ATF3 relationships, ubiquitin-linked stability, and protein-complex composition in intervertebral disc degeneration models. The Protein A/G Magnetic Co-IP/IP Kit combines Fc-selective capture, rapid magnetic handling, and SDS-PAGE- or mass spectrometry-ready elution for reproducible interaction studies.
-
Dicoumarol Targets IRE1α in ER Stress Liver Injury
2026-08-27
Yang and colleagues developed a screening workflow that combines kinase-domain molecular docking with an XBP1s reporter assay to identify dicoumarol as an inhibitor of IRE1α activation. The compound reduced tunicamycin- and carbon tetrachloride-associated endoplasmic reticulum stress and protected mice from acute liver injury, providing a mechanistically focused route for compound discovery.
-
Estradiol–Autophagy Axis in Perimenopausal Aging
2026-08-27
This study integrates NHANES analysis, network pharmacology, and perimenopausal mouse experiments to examine how declining estradiol relates to multi-organ disease risk. Its central contribution is mechanistic evidence that estrogen receptor activity and downstream autophagy jointly protect the heart, aorta, and kidneys from fibrosis during perimenopausal aging.
-
Norepinephrine Bitartrate: A Dose-Aware Research Guide
2026-08-26
Norepinephrine bitartrate connects adrenergic receptor biology with dose-aware cardiovascular research. This guide interprets clinical vasopressor conversion data for assay design without confusing clinical dose ratios with in vitro concentration equivalence.
-
15-PGDH Inhibition During Semaglutide Weight Loss
2026-08-26
The reference study identifies 15-PGDH inhibition as a complementary strategy for maintaining muscle quality during semaglutide-associated weight loss. In obese mice, combining a 15-PGDH inhibitor with semaglutide improved muscle stem cell activity, regenerated myofiber growth, and force recovery without reducing the drug’s weight-loss effect.
-
Mast Cell–Mesothelial Crosstalk in Peritoneal Fibrosis
2026-08-25
Chen et al. identify tryptase/PAR2 signaling as a mechanistic link between mast-cell activation and peritoneal mesothelial fibrosis during exposure to high-glucose peritoneal dialysis fluid. Using chemical profiling, multi-omics, cell models, and a mouse model, the study shows that Astragalus membranaceus and Salvia miltiorrhiza suppress mast-cell degranulation and downstream MAPK/NF-κB signaling, providing a framework for investigating inflammatory crosstalk in peritoneal fibrosis.
-
HRP Goat Anti-Mouse IgG: Assay Design for CRC
2026-08-25
Discover how Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP Conjugated supports orthogonal validation of AQP9 biology in KRASG12V colorectal cancer. This guide connects secondary-antibody chemistry with assay controls, tissue interpretation, and reproducible Western blot, ELISA, IHC, and ICC workflows.
-
Puromycin and Precision Gene Therapy Workflows
2026-08-24
Puromycin dihydrochloride is more than a routine selection reagent. Its defined ribosomal mechanism can sharpen cell-engineering workflows, while recent AAV capsid research shows how disciplined functional validation can support more precise gene-delivery strategies.
-
H-89 in Wnt–PKA Osteoblast Assays
2026-08-24
H-89 is a cAMP-dependent protein kinase inhibitor that helps resolve how Wnt-triggered PKA activity influences O-GlcNAcylation, glycolysis, and osteoblast formation. This article presents an assay-centered framework for separating pathway timing, metabolic effects, and inhibitor-specific limitations.
-
1-methyl Adenosine: Assay Workflows & Applications
2026-08-23
1-methyl Adenosine, also called 1-methyl Ado or m1A, connects modified-nucleoside biology with targeted cellular metabolomics. This guide translates stable isotope-diluted UHPLC–MS/MS findings into practical workflows for RNA modification research, cancer metabolism studies, biomarker discovery, and therapeutic target validation.